Brain-Targeted Drug Delivery
Brain diseases currently affect one in six people worldwide; they include a wide range of neurological diseases, from Alzheimer’s and Parkinson’s diseases to epilepsy, brain injuries, brain cancer, neuroinfections, and strokes. The treatment of these diseases is complex and limited due to the presen...
Saved in:
Sonstige: | |
---|---|
Year of Publication: | 2022 |
Language: | English |
Physical Description: | 1 electronic resource (260 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993562966304498 |
---|---|
ctrlnum |
(CKB)5670000000391602 (oapen)https://directory.doabooks.org/handle/20.500.12854/93194 (EXLCZ)995670000000391602 |
collection |
bib_alma |
record_format |
marc |
spelling |
Sousa, Flávia edt Brain-Targeted Drug Delivery MDPI - Multidisciplinary Digital Publishing Institute 2022 1 electronic resource (260 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Open access Unrestricted online access star Brain diseases currently affect one in six people worldwide; they include a wide range of neurological diseases, from Alzheimer’s and Parkinson’s diseases to epilepsy, brain injuries, brain cancer, neuroinfections, and strokes. The treatment of these diseases is complex and limited due to the presence of the blood–brain barrier (BBB), which covers the entirety of the brain. The BBB not only has the function of protecting the brain from harmful substances; it is also a metabolic barrier and a transport regulator of nutrients/serum factors/neurotoxins. Knowing these characteristics when it comes to the treatment of brain diseases makes it easier to understand the lack of efficacy of therapeutic drugs, resulting from the innate resistance of the BBB to permeation. To overcome this limitation, drug delivery systems based on nanotechnology/microtechnology have been developed. Brain-targeted drug delivery enables targeted therapy with a higher therapeutic efficacy and fewer side effects because it targets moieties present in the drug delivery systems. English Technology: general issues bicssc drug delivery into the brain transendothelium based on receptor-mediated transcytosis immunotherapy Alzheimer's disease anti-tau and anti-receptor bispecific monoclonal antibodies Alzheimer's disease-relevant tau species temporal-spatial pathological Aβ and tau distribution interactions between Aβ and tau tau clearance in microglia tau clearance in neurons liposome nanoparticle seizure laser ultrasound naringenin nanostructured lipid carrier intranasal delivery central composite rotatable design depression pomegranate seed oil nasal delivery system memory impairment movement impairment delivery to brain improved memory phospholipid oily gel high-grade glioma diffuse midline glioma glioblastoma IL-13Rα2 IL-13 immunotoxin targeted therapy GB-13 IL13.E13K-PE4E receptor expression acetaminophen blood-brain barrier claudin-5 CNS drug delivery opioids tight junction microdialysis cerebral open flow microperfusion electrochemical biosensors macromolecules tolcapone microparticles nanoparticles PLGA Parkinson's disease nose to brain delivery gene therapy polyplexes hyaluronidase glycol chitosan brain cancer chemoattractant CXCL CXCR glioblastoma multiforme 3D cell culture systems non-human primate convection-enhanced delivery neurosurgery optogenetics brain targeted therapy drug delivery cerebrospinal fluid microcirculation brain biodistribution 3-0365-5282-0 Sousa, Flávia oth |
language |
English |
format |
eBook |
author2 |
Sousa, Flávia |
author_facet |
Sousa, Flávia |
author2_variant |
f s fs |
author2_role |
Sonstige |
title |
Brain-Targeted Drug Delivery |
spellingShingle |
Brain-Targeted Drug Delivery |
title_full |
Brain-Targeted Drug Delivery |
title_fullStr |
Brain-Targeted Drug Delivery |
title_full_unstemmed |
Brain-Targeted Drug Delivery |
title_auth |
Brain-Targeted Drug Delivery |
title_new |
Brain-Targeted Drug Delivery |
title_sort |
brain-targeted drug delivery |
publisher |
MDPI - Multidisciplinary Digital Publishing Institute |
publishDate |
2022 |
physical |
1 electronic resource (260 p.) |
isbn |
3-0365-5281-2 3-0365-5282-0 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT sousaflavia braintargeteddrugdelivery |
status_str |
n |
ids_txt_mv |
(CKB)5670000000391602 (oapen)https://directory.doabooks.org/handle/20.500.12854/93194 (EXLCZ)995670000000391602 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Brain-Targeted Drug Delivery |
author2_original_writing_str_mv |
noLinkedField |
_version_ |
1806051799463886848 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04583nam-a2201165z--4500</leader><controlfield tag="001">993562966304498</controlfield><controlfield tag="005">20240729172135.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202210s2022 xx |||||o ||| 0|eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3-0365-5281-2</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5670000000391602</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/93194</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995670000000391602</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Sousa, Flávia</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Brain-Targeted Drug Delivery</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (260 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="506" ind1=" " ind2=" "><subfield code="a">Open access</subfield><subfield code="f">Unrestricted online access</subfield><subfield code="2">star</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Brain diseases currently affect one in six people worldwide; they include a wide range of neurological diseases, from Alzheimer’s and Parkinson’s diseases to epilepsy, brain injuries, brain cancer, neuroinfections, and strokes. The treatment of these diseases is complex and limited due to the presence of the blood–brain barrier (BBB), which covers the entirety of the brain. The BBB not only has the function of protecting the brain from harmful substances; it is also a metabolic barrier and a transport regulator of nutrients/serum factors/neurotoxins. Knowing these characteristics when it comes to the treatment of brain diseases makes it easier to understand the lack of efficacy of therapeutic drugs, resulting from the innate resistance of the BBB to permeation. To overcome this limitation, drug delivery systems based on nanotechnology/microtechnology have been developed. Brain-targeted drug delivery enables targeted therapy with a higher therapeutic efficacy and fewer side effects because it targets moieties present in the drug delivery systems.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Technology: general issues</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug delivery into the brain</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">transendothelium based on receptor-mediated transcytosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Alzheimer's disease</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">anti-tau and anti-receptor bispecific monoclonal antibodies</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Alzheimer's disease-relevant tau species</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">temporal-spatial pathological Aβ and tau distribution</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">interactions between Aβ and tau</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tau clearance in microglia</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tau clearance in neurons</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">liposome</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nanoparticle</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">seizure</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">laser</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ultrasound</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">naringenin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nanostructured lipid carrier</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">intranasal delivery</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">central composite rotatable design</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">depression</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pomegranate seed oil</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nasal delivery system</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">memory impairment</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">movement impairment</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">delivery to brain</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">improved memory</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">phospholipid oily gel</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">high-grade glioma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">diffuse midline glioma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">glioblastoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">IL-13Rα2</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">IL-13</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunotoxin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">targeted therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">GB-13</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">IL13.E13K-PE4E</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">receptor expression</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">acetaminophen</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">blood-brain barrier</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">claudin-5</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CNS drug delivery</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">opioids</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tight junction</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">microdialysis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cerebral open flow microperfusion</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">electrochemical biosensors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">macromolecules</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tolcapone</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">microparticles</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nanoparticles</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PLGA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Parkinson's disease</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nose to brain delivery</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">gene therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">polyplexes</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">hyaluronidase</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">glycol chitosan</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">brain cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">chemoattractant</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CXCL</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CXCR</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">glioblastoma multiforme</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">3D cell culture systems</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">non-human primate</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">convection-enhanced delivery</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">neurosurgery</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">optogenetics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">blood-brain barrier</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">brain targeted therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug delivery</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cerebrospinal fluid microcirculation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">brain biodistribution</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-5282-0</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sousa, Flávia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2024-07-31 00:09:10 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-11-05 21:33:14 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5340569500004498&Force_direct=true</subfield><subfield code="Z">5340569500004498</subfield><subfield code="b">Available</subfield><subfield code="8">5340569500004498</subfield></datafield></record></collection> |